A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature
Overview
Authors
Affiliations
In this issue of Cancer Cell, Seaman et al. demonstrate that antibody drug conjugates (ADCs) against CD276 expressed by tumor cells and tumor vasculature have promising anti-tumor activity while showing little toxicity. Importantly, these agents have the potential to target both angiogenic vessels and non-angiogenic vessels co-opted by tumor cells.
Meeus F, Funeh C, Awad R, Zeven K, Autaers D, De Becker A J Immunother Cancer. 2024; 12(11).
PMID: 39562005 PMC: 11575280. DOI: 10.1136/jitc-2024-009110.
Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics.
Ren E, Liu C, Lv P, Wang J, Liu G Adv Sci (Weinh). 2021; 8(21):e2100460.
PMID: 34494387 PMC: 8564451. DOI: 10.1002/advs.202100460.
C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.
Khan K, McMurray J, Mohammed F, Bicknell R FEBS J. 2019; 286(17):3299-3332.
PMID: 31287944 PMC: 6852297. DOI: 10.1111/febs.14985.
Kuczynski E, Vermeulen P, Pezzella F, Kerbel R, Reynolds A Nat Rev Clin Oncol. 2019; 16(8):469-493.
PMID: 30816337 DOI: 10.1038/s41571-019-0181-9.
Non-angiogenic tumours and their influence on cancer biology.
Donnem T, Reynolds A, Kuczynski E, Gatter K, Vermeulen P, Kerbel R Nat Rev Cancer. 2018; 18(5):323-336.
PMID: 29520090 DOI: 10.1038/nrc.2018.14.